Zydus Launches IBYRA, the Generic Version of Olaparib, Brings Both Access and Affordability for Cancer Patients in India

Mar 14, 2024

Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor,...

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Oct 26, 2021

Mumbai (Maharashtra) [India], October 26 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed-dose combination (FDC) of its novel,...

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet

Jul 19, 2023

Seoul [South Korea], July 19: Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo...

Daewoong Pharmaceutical announce Publication of Phase 3 Study of 'Envlo', a new treatment for Diabetes, in the International SCIE Journal

Apr 24, 2023

Seoul [South Korea], April 24 (ANI/PRNewswire): The research results of Daewoong Pharmaceutical's SGLT-2 inhibitor new drug, 'Envlo', have been internationally acknowledged.

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Dec 29, 2020

Mumbai (Maharashtra) [India], December 29 . (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of...

Frontier Biotechnologies announces positive phase 1 results of its first coronavirus main protease (Mpro) small molecule inhibitor

Aug 10, 2022

Atlanta (Georgia) [US], August 10 (ANI/PRNewswire): Frontier Biotechnologies, a biopharmaceutical company focused on the discovery, development and dissemination of innovative medicines that improve patient...